Published in HIV AIDS (Auckl) on December 14, 2011
Assessing appearance-related disturbances in HIV-infected men who have sex with men (MSM): psychometrics of the body change and distress questionnaire-short form (ABCD-SF). AIDS Behav (2014) 0.82
Alcoholic Extract of Lotus Leaves Improves Lipid Profile in Rats with HIV Protease Inhibitor-induced Dyslipidaemia. West Indian Med J (2015) 0.75
Lipodystrophy HIV-related and FGF21: A new marker to follow the progression of lipodystrophy? J Transl Int Med (2016) 0.75
Atherosclerosis--an inflammatory disease. N Engl J Med (1999) 59.28
CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med (2006) 22.76
Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med (2008) 13.72
Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med (2003) 12.23
Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr (2006) 12.07
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA (2004) 10.40
A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS (1998) 8.88
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med (2006) 8.35
Acquired and inherited lipodystrophies. N Engl J Med (2004) 7.22
HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med (2011) 6.30
Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med (1995) 5.98
Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab (1992) 4.25
The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr (1956) 4.11
Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr (2005) 4.02
Impact of HIV infection and HAART on serum lipids in men. JAMA (2003) 4.01
Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr (2001) 3.83
Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol (2008) 3.36
Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr (2002) 3.33
Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med (2007) 3.13
Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med (2003) 2.64
The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem (2000) 2.55
An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet (2003) 2.43
The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med (2006) 2.38
Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab (1997) 2.31
Fat distribution in women with HIV infection. J Acquir Immune Defic Syndr (2006) 2.15
HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med (2001) 2.14
Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr (2002) 1.98
Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS (2003) 1.97
Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. Am J Physiol Endocrinol Metab (2007) 1.97
Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS (2001) 1.90
HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS (2009) 1.88
Fat distribution and metabolic changes in patients with HIV infection. AIDS (1999) 1.67
Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS (2004) 1.61
Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS (2000) 1.60
Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis (2006) 1.42
Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J Acquir Immune Defic Syndr (2004) 1.39
Body composition and metabolic effects of a diet and exercise weight loss regimen on obese, HIV-infected women. Metabolism (2006) 1.29
Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy. AIDS (2008) 1.18
Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med (1991) 1.15
Longitudinal increases in waist circumference are associated with HIV-serostatus, independent of antiretroviral therapy. AIDS (2007) 1.09
Exercise training augments the peripheral insulin-sensitizing effects of pioglitazone in HIV-infected adults with insulin resistance and central adiposity. Am J Physiol Endocrinol Metab (2010) 1.03
Dietary fat intake and relationship to serum lipid levels in HIV-infected patients with metabolic abnormalities in the HAART era. AIDS (2007) 1.01
Genetic analysis implicates resistin in HIV lipodystrophy. AIDS (2008) 0.96
Validation of a specific questionnaire on psychological and social repercussions of the lipodystrophy syndrome in HIV-infected patients. Qual Life Res (2006) 0.92
Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production. Arterioscler Thromb Vasc Biol (2009) 0.92
How much fat loss is needed for lipoatrophy to become clinically evident? AIDS Res Hum Retroviruses (2009) 0.91
Antiretroviral therapy affects the composition of weight loss in HIV infection: implications for clinical nutrition. Clin Nutr (2005) 0.82
Body mass index and waist circumference independently contribute to the prediction of nonabdominal, abdominal subcutaneous, and visceral fat. Am J Clin Nutr (2002) 3.33
State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation (2008) 2.17
Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr (2002) 1.98
Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol (2007) 1.90
Body-size dependence of resting energy expenditure can be attributed to nonenergetic homogeneity of fat-free mass. Am J Physiol Endocrinol Metab (2002) 1.82
Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV. Am J Gastroenterol (2007) 1.77
Independent associations of insulin resistance with high whole-body intermuscular and low leg subcutaneous adipose tissue distribution in obese HIV-infected women. Am J Clin Nutr (2007) 1.63
Intermuscular adipose tissue-free skeletal muscle mass: estimation by dual-energy X-ray absorptiometry in adults. J Appl Physiol (1985) (2004) 1.57
Effect of recombinant human growth hormone on exercise capacity in patients with HIV-associated wasting on HAART. AIDS Read (2005) 1.40
Association of antiretroviral therapy with fibrinogen levels in HIV-infection. AIDS (2008) 1.38
Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy. J Acquir Immune Defic Syndr (2007) 1.37
Body cell mass: model development and validation at the cellular level of body composition. Am J Physiol Endocrinol Metab (2003) 1.33
Body composition and metabolic effects of a diet and exercise weight loss regimen on obese, HIV-infected women. Metabolism (2006) 1.29
HIV infection and the gastrointestinal tract. AIDS (2005) 1.26
Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors. Circulation (2008) 1.24
Relationship of fat distribution with adipokines in human immunodeficiency virus infection. J Clin Endocrinol Metab (2007) 1.24
Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy. Am J Physiol Endocrinol Metab (2003) 1.19
Insulin resistance, glucose intolerance and diabetes mellitus in HIV-infected patients. Antivir Ther (2007) 1.14
Accelerated gastric emptying but no carbohydrate malabsorption 1 year after gastric bypass surgery (GBP). Obes Surg (2012) 1.07
Bone mineral content is lower in prepubertal HIV-infected children. J Acquir Immune Defic Syndr (2002) 1.06
Multicomponent methods: evaluation of new and traditional soft tissue mineral models by in vivo neutron activation analysis. Am J Clin Nutr (2002) 1.03
The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications. Toxicol Pathol (2009) 1.01
Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. J Acquir Immune Defic Syndr (2002) 1.01
Clinical evaluation and management of metabolic and morphologic abnormalities associated with human immunodeficiency virus. Clin Infect Dis (2001) 1.01
Total body protein: a new cellular level mass and distribution prediction model. Am J Clin Nutr (2003) 0.98
Liver pathology in morbidly obese patients undergoing Roux-en-Y gastric bypass surgery. Obes Surg (2002) 0.98
The virotoxin model of HIV-1 enteropathy: involvement of GPR15/Bob and galactosylceramide in the cytopathic effects induced by HIV-1 gp120 in the HT-29-D4 intestinal cell line. J Biomed Sci (2003) 0.97
Age-related skeletal muscle decline is similar in HIV-infected and uninfected individuals. J Gerontol A Biol Sci Med Sci (2011) 0.96
Lymphogranuloma venereum in human immunodeficiency virus-infected individuals in New York City. J Clin Gastroenterol (2006) 0.95
HIV enteropathy: crypt stem and transit cell hyperproliferation induces villous atrophy in HIV/Microsporidia-infected jejunal mucosa. AIDS (2007) 0.94
Growth hormone improves lean body mass, physical performance, and quality of life in subjects with HIV-associated weight loss or wasting on highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2004) 0.94
Oxandrolone in the treatment of HIV-associated weight loss in men: a randomized, double-blind, placebo-controlled study. J Acquir Immune Defic Syndr (2006) 0.89
Effects of growth hormone on visceral adipose tissue and dyslipidemia in HIV, an erratum. J Acquir Immune Defic Syndr (2006) 0.86
Regional adipose tissue and elevations in serum aminotransferases in HIV-infected individuals. J Acquir Immune Defic Syndr (2008) 0.85
The prevalence and pathogenesis of diabetes mellitus in treated HIV-infection. Best Pract Res Clin Endocrinol Metab (2011) 0.85
Treatment of chronic hepatitis C virus infection in the United States: some remaining obstacles. Liver Int (2014) 0.83
Effect of HIV infection on body composition and fat distribution in Rwandan women. J Int Assoc Physicians AIDS Care (Chic) (2010) 0.82
HIV enteropathy and aging: gastrointestinal immunity, mucosal epithelial barrier, and microbial translocation. Curr Opin HIV AIDS (2014) 0.82
A Case of Staphylococcus aureus Enterocolitis: A Rare Entity. Gastroenterol Hepatol (N Y) (2010) 0.81
Insulin resistance, hepatic lipid and adipose tissue distribution in HIV-infected men. Antivir Ther (2008) 0.80
Gastric carcinoids in a patient with pernicious anemia and familial adenomatous polyposis. J Clin Gastroenterol (2002) 0.80
Gastric toxoplasmosis as the presentation of acquired immunodeficiency syndrome. Arch Pathol Lab Med (2005) 0.79
Preferential loss of omental-mesenteric fat during growth hormone therapy of HIV-associated lipodystrophy. J Appl Physiol (1985) (2003) 0.79
Intermuscular adipose tissue and metabolic associations in HIV infection. Obesity (Silver Spring) (2010) 0.78
Staphylococcal enterocolitis: forgotten but not gone? Dig Dis Sci (2009) 0.78
Effect of HIV infection on the prevalence of colorectal adenomas during screening colonoscopy. J Clin Gastroenterol (2010) 0.77
Use of a Durnin-Womersley formula to estimate change in subcutaneous fat content in HIV-infected subjects. Am J Clin Nutr (2002) 0.77
Teaching the competencies: using observed structured clinical examinations for faculty development. Am J Gastroenterol (2010) 0.77
HIV enteropathy: HAART reduces HIV-induced stem cell hyperproliferation and crypt hypertrophy to normal in jejunal mucosa. J Clin Pathol (2013) 0.76
A comparison of abdominal subcutaneous adipose tissue pattern in obese and lean HIV-infected women. J Nutr (2005) 0.76
Developing an objective evaluation method to estimate diabetes risk in community-based settings. Diabetes Technol Ther (2011) 0.75
Editorial comment: tackling the causes of lipoatrophy--not for the fainthearted. AIDS Read (2003) 0.75
Diabetes mellitus, HIV infection, and vitamin D: time to act or time to think? AIDS (2011) 0.75
HIV and insulin resistance in context. AIDS Read (2005) 0.75
Validation of an elliptical anthropometric model to estimate visceral compartment area. Obes Res (2004) 0.75
Detection of segmental internal fat by bioelectrical impedance analysis in a biological phantom. Nutrition (2003) 0.75
Relative effects of heavy alcohol use and hepatitis C in decompensated chronic liver disease in a hospital inpatient population. Am J Drug Alcohol Abuse (2014) 0.75